ERBB2 and neoplasm: A study of more than 400 patients with tamoxifen-treated ER-positive breast cancer found that patients whose tumours were also positive for HER2 and HER3 are more likely to relapse while on tamoxifen than those with HER2- and HER3-negative tumours [43].